Your browser doesn't support javascript.
loading
Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD.
Tamaki, Nobuharu; Munaganuru, Nagambika; Jung, Jinho; Yonan, Aed Qas; Bettencourt, Richele; Ajmera, Veeral; Valasek, Mark A; Behling, Cynthia; Loomba, Rohit.
Affiliation
  • Tamaki N; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Munaganuru N; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California.
  • Jung J; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California.
  • Yonan AQ; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California.
  • Bettencourt R; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California.
  • Ajmera V; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California.
  • Valasek MA; Department of Pathology, University of California at San Diego, La Jolla, California.
  • Behling C; Sharp Medical Group, Department of Pathology, University of California at San Diego, La Jolla, California.
  • Loomba R; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California. Electronic address: roloomba@ucsd.edu.
Clin Gastroenterol Hepatol ; 19(12): 2673-2674.e3, 2021 12.
Article in En | MEDLINE | ID: mdl-33157318
ABSTRACT
The Nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) has been applied as a method for evaluating treatment response, and a ≥2-point improvement in NAS has been commonly used as an accepted end point in phase 2b clinical trials in nonalcoholic steatohepatitis.1,2 Although liver fibrosis is the strongest histologic predictor of liver-related outcome and all-cause mortality in NAFLD,3,4 the association between change in NAS and change in fibrosis stage has not been fully verified. Therefore, we aimed to examine the association between change in NAS and change in fibrosis stage in well-characterized patients with NAFLD who had a paired liver biopsy assessment.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Non-alcoholic Fatty Liver Disease Type of study: Diagnostic_studies / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2021 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Non-alcoholic Fatty Liver Disease Type of study: Diagnostic_studies / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2021 Document type: Article Affiliation country: